All In Biotech

Drug Trial Radar · NCT00283335

The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

Last checked: Nov 20, 2026Latest source record: Oct 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,531 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,531

Actual

Start

Jun 1991

Primary completion

Sep 1998

Study completion Aug 1999

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
Collaborators
Parke-Davis; Fournier Labs
First posted
Jan 27, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, up to 73 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a double-blind randomized trial comparing 1200 mg per day of gemfibrozil with placebo in 2531 men with coronary heart disease, an HDL-C of 40mg/dl or less, an LDL-C of 140 mg/dl or less, and triglycerides of 300mg/dl or less. The primary outcome was nonfatal myocardial infarction(MI) or death from coronary causes. The median follow-up was 5.1 years. There was a risk reduction of 22% in the primary outcome (p=.0006) and 24% risk reduction in the combined endpoint of stroke, MI, and CHD death. The rate of events was reduced by raising HDL-C and lowering triglycerides without lowering LDL-C (N Engl J Med 1999;341:410-418).

Conditions

  • Coronary Heart Disease

Interventions

  • gemfibrozilDrug

  • PlaceboOther

    Matching placebo tablets taken once per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. incidence of nonfatal myocardial infarction or death from coronary heart diseaseTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Minneapolis VA Health Care System, Minneapolis, MN

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.